H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock

H.C. Wainwright reiterated a Buy rating on ORIC Pharmaceuticals and a $25 price target, implying meaningful upside from the $7.50 share price and above the 52-week low of $7.23. The firm said ORIC’s rinzimetostat has not shown secondary malignancies in clinical or non-clinical toxicology studies, contrasting with prior PRC2 inhibitors that raised safety concerns. Sentiment is supported by broader analyst enthusiasm, including Goldman Sachs’ upgrade and peak sales estimate of $2.6 billion, though the stock remains under pressure after a 16% weekly decline.

Analysis

The setup is less about the near-term read-through from one trial update and more about whether ORIC can convert a clean safety narrative into a durable valuation rerating before the market re-prices the program as another me-too epigenetic asset. The key second-order effect is on probability-weighted partnering: if rinzometostat keeps avoiding the malignancy baggage that has handicapped this class, ORIC’s bargaining power improves materially, because larger oncology partners will pay up for de-risked biology with cleaner regulator optics.

FULC is the clearest loser, but the bigger implication is for the PRC2 bucket as a whole. Negative spillovers from one failed program often compress multiples across adjacent early-stage epigenetic names for weeks, even when the underlying mechanism is different; that creates a window for relative-value trades rather than outright directional shorts. PFE matters mainly as a comparator: if Pfizer’s competing asset continues to look merely adequate, ORIC can still win on differentiation even without blowout efficacy, because safety plus tolerability can dominate in combination regimens where chronic dosing matters.

The main contrarian risk is that the market may be over-anchoring on a clean toxicology package and underweighting the far more important issue: eventual efficacy durability and whether the PSA signal translates into OS or rPFS in a crowded prostate landscape. If subsequent data show plateauing responses or more dose pressure, today’s safety premium will fade quickly over the next 1-2 quarters. Conversely, a positive partnership or expansion update within 3-6 months could force a sharp re-rating because current pricing implies limited confidence in a path to commercial relevance.

For now, the move looks under-owned rather than over-extended, but the trade is likely to be choppy: ORIC can rerate on headlines while FULC remains a slow-burn loser from class contamination. The best risk/reward is to express the view as a relative trade with defined downside, not as a naked long biotech beta bet.

Key Decisions for Investors

• Long ORIC / short FULC as a 1-3 month pair trade: ORIC benefits from class differentiation while FULC absorbs the reputational overhang from PRC2 safety concerns; target 15-25% relative outperformance, stop if ORIC loses the safety edge in upcoming data.
• Buy ORIC call spreads out 3-6 months (e.g., 10/15 or 12.5/20) into the next clinical or partnering catalyst: limited premium outlay for a binary rerating if the market starts assigning higher partnership probability.
• If already long ORIC equity, hedge with short-dated puts into data windows: the stock is sensitive to efficacy disappointment, and a 20-30% drawdown remains plausible if the next readout is merely confirmatory rather than clearly superior.
• Avoid chasing FULC on any reflexive bounce for the next several weeks: this is a class-confidence reset, and recoveries after mechanism-level safety scares usually take multiple months unless there is a clearly differentiated dataset.
• Use PFE only as a sentiment hedge, not a standalone alpha idea: if ORIC’s competitor continues to look incremental, that supports ORIC's relative story; if PFE surprises positively, it compresses ORIC's upside by reducing perceived differentiation.